Nonacog alfa

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

42 competitors in Hemophilia B

#DrugCompanyPhaseTrials

1

Recombinant Factor IX Coagulation

Pfizer

Approved

22

IB1001

MMedexus Pharma, Inc.

Phase 3

33

Translarna

PPTC Therapeutics

Phase 2

—4

BENEFIX

Pfizer

Phase 3

65

Recombinant Factor IX

BBaxalta now part of Shire

Phase 3

16

Rfix

Pfizer

Phase 3

37

Factor Ix

CSL Behring

Phase 3

38

Rix-FP

CSL Behring

Phase 3

39

Rfixfc

BBioverativ Therapeutics Inc.

Phase 3

410

RG7916

Roche

Phase 2

—Show 9 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hemophilia B3 trials

Study To Compare On-Demand Treatment To A Prophylaxis Regimen Of BeneFIX In Subjects With Moderately Severe to Severe Hemophilia B

Completed·Pfizer·Phase 3·NCT01335061·25 enrolled

Nonacog Alfa Prophylaxis And Treatment Of Bleeding Episodes In Previously Treated Patients With Hemophilia B

Completed·Pfizer·Phase 4·NCT04286412·25 enrolled

Study of Recombinant Factor IX Product, IB1001, in Subjects With Hemophilia B

Completed·MMedexus Pharma, Inc.·Phase 2/3·NCT00768287·77 enrolled

Drug1 trial

BeneFIX Drug Use Results Survey [All-Case Surveillance]

Completed·Pfizer··NCT01154231·314 enrolled

Details

Drug Info

Related News